# Lifespan Investments

> Lifespan Investments is a VC fund backing Biotechnology, Medical and Biopharma. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 5
- Last investment: Dec 2022
- Lead investor: 20%
- Last updated: Aug 2026

Lifespan Investments is a VC fund focused on Biotechnology and Medical. Lifespan Investments

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 100% |
| Medical | 3 | 60% |
| Biopharma | 2 | 40% |
| Information Technology | 2 | 40% |
| Genetics | 1 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 80% |
| Series B | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SonoThera | SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $60.8M | Series A | Dec 05, 2022 |  |
| Amberstone Biosciences | Amberstone Biosciences discovers novel immunotherapies through innovative technologies and creative partnerships.Amberstone's focus is difficult targets requiring a unique mode-of-action and/or particular functional property, which are otherwise challenging for traditional approaches.These conventional limitations are overcome via atwo-pronged approach. First, we have demonstrated success with our microfluidics-powered AmberFlow drug-discovery platform. Second, our team of experts has keen insights in immuno-oncology and ample experience with single-cell assay biology. | $12M | Series A | Jan 03, 2022 |  |
| Akadeum Life Sciences | Akadeum Life Sciences is working on the problem of isolating mammalian and bacterial cells from complex mixtures. It creates the simplest bioseparation products and fundamentally change the way that isolating cells and other biological targets approached. The company currently uses microbubbles for applications in cell separation and other relatedareas.Akadeum Life Sciences was founded in 2014 and is headquartered in Ann Arbor, Michigan, United States. | $17.5M | Series B | Oct 12, 2021 |  |
| Teon Therapeutics | Teon Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing a focused portfolio of small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways in the tumor microenvironment. Teon's lead program is an A2BR-specific antagonist that will enterPhase1b trials in 2021. | $30M | Series A | Feb 23, 2021 |  |
| Cardea Bio | Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors. Cardean transistors leverage biocompatible graphene instead of silicon and replace optical signal observations with direct electrical molecular signal analysis. With Cardean transistors, the company and its Innovation Partners cangenerate streaming multi-omics data to measure real-time biological signals. Cardea is now manufacturing chips at scale and partners have started to significantly expand the amount, type, and quality of biological data they capture by building products that Conduct Biolog. | $7.5M | Series A | Sep 17, 2020 |  |

5 of 5 investments shown.

## Co-investors
- [Agilent Technologies](https://shizune.co/investors/profile/agilent) — VC Fund, 2 deals together
- [Foothill Ventures](https://shizune.co/investors/profile/tsingyuan-ventures) — VC Fund, 2 deals together
- [Arboretum Ventures](https://shizune.co/investors/profile/arboretum-ventures) — VC Fund, 1 deal together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 1 deal together
- [Beringea](https://shizune.co/investors/profile/beringea) — VC Fund, 1 deal together
- [Berkeley Catalyst Fund (BCF)](https://shizune.co/investors/profile/berkeley-catalyst-fund-bcf) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Lifespan Investments invest in?

Lifespan Investments invests primarily in Biotechnology, Medical and Biopharma startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Lifespan Investments last invest?

The most recent investment recorded for Lifespan Investments closed in Dec 2022. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co